natgillin/translations-raw huggingface dataset:
The capsule is a yellow cap/white body hard capsule of 23.4 mm, printed with black ink imprinted with “40 mg” on body and “A733” on cap.
Kapsula je trda kapsula z rumenim pokrovčkom/belim telesom, velika 23,4 mm, s črnima oznakama „40 mg“ na telesu in „A733“ na pokrovčku.
The dose of lomitapide was escalated from 5 mg to an individually determined maximum tolerated dose up to 60 mg. After Week 26, patients remained on lomitapide to determine the effects of longer-term treatment and were allowed to change background lipid-lowering therapies.
Po 26. tednu so bolniki nadaljevali z jemanjem lomitapida, s čimer so želeli ugotoviti učinke dolgotrajnega zdravljenja.
Table 4 lists all adverse reactions for subjects who received lomitapide monotherapy (N=291) treated in Phase 2 studies in subjects with elevated LDL-C (N=462).
(N = 291) v študijah 2. faze, ki so vključevale bolnike s povečano koncentracijo holesterola LDL
• Patients with a known significant or chronic bowel disease such as inflammatory bowel disease or malabsorption.
• bolniki s potrjeno pomembno ali kronično črevesno boleznijo, kot je vnetna črevesna bolezen ali malabsorpcija; • sočasna uporaba > 40 mg simvastatina (glejte poglavje 4.5);
Hard, capsule.
Ovojnica kapsule
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo!
There was no evidence of embryofoetal toxicity in rabbits at 3 times the maximum recommended human dose (MRHD) of 60 mg based on body surface area.
Dokazov o toksičnosti za zarodek in plod pri kuncih, pri katerih je bil odmerek 3-krat večji od največjega priporočenega odmerka pri človeku, 60 mg, na podlagi telesne površine, ni. Toksičnost za zarodek in plod so opazili pri kuncih pri ≥ 6,5-kratnem največjem priporočenem odmerku pri človeku, vendar brez toksičnosti za mater.
Diarrhoea Nausea Flatulence
Bolezni jeter, žolčnika in žolčevodov
(E172) and yellow iron oxide (E172).
rumeni železov oksid (E 172)
• Not to take Lojuxta if patient has liver problems, or unexplained abnormal liver tests;
Brošura za bolnike mora vsebovati naslednje ključne elemente: • Ne jemljite zdravila Lojuxta, če imate težave z jetri ali nenormalne rezultate preiskav jetrnega delovanja; • Informacije, da lahko zdravilo Lojuxta povzroči težave z jetri;
The dose of Lojuxta should be taken 12 hours apart from any other concomitant weak CYP3A4 inhibitors.
Odmerek zdravila Lojuxta je treba vzeti z 12-urnim zamikom glede na sočasno uporabo drugih šibkih
Diarrhoea
Bolezni živčevja
• medicines to treat and prevent blood clots (e.g. cilostazol, ticagrelor)
• zdravila za zdravljenje in preprečevanje krvnih strdkov (npr. cilostazol, tikagrelor), • zdravila za zdravljenje angine - bolečine v prsnem košu, ki jo povzroča srce (npr. ranolazin),
Grapefruit juice is a moderate inhibitor of CYP3A4 and is expected to substantially increase exposure to lomitapide.
CYP3A4, zato se pričakuje, da bo pomembno povečal izpostavljenost lomitapidu.
• flatulence (wind)
• vetrovi,
When the dose of lomitapide was taken 12 hours apart from atorvastatin,
Pri uporabi odmerka lomitapida z 12-urnim zamikom glede na uporabo atorvastatina niso opazili klinično pomembnega povečanja izpostavljenosti lomitapidu.
Abdominal pain Abdominal pain upper Flatulence
Zelo pogosti diareja, navzea, flatulenca
CYP3A4, lomitapide AUC increased approximately 27-fold and Cmax increased approximately 15-fold.
200 mg dvakrat na dan, se je vrednost AUC lomitapida povečala za približno 27-krat,
Exercise additional caution if administering more than 1 weak CYP3A4 inhibitor with Lojuxta.
Pri sočasni uporabi šibkega zaviralca CYP3A4 in zdravila Lojuxta je potrebna posebna previdnost.
Decreased appetite
distenzija trebuha,
This summary was last updated in 01-2017.
Povzetek je bil nazadnje posodobljen 01-2017.
On average, patients in the study were followed up for 3.1 years.
V povprečju so bolnike v študiji spremljali 3,1 leta.
Supportive evidence was provided from a further six studies.
Podporni dokazi so bili zagotovljeni v šestih nadaljnjih študijah.
The European Commission granted a marketing authorisation valid throughout the European Union for Jardiance on 22 May 2014.
Evropska komisija je dovoljenje za promet z zdravilom Jardiance, veljavno po vsej Evropski uniji, izdala 22. maja 2014.
The recommended starting dose is 10 mg once a day, which can be increased if necessary to 25 mg daily in suitable patients.
Priporočeni začetni odmerek je 10 mg enkrat na dan, ki se lahko po potrebi poveča na 25 mg dnevno pri bolnikih, ki so za to primerni.
What measures are being taken to ensure the safe and effective use of Jardiance?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Jardiance?
Regarding safety, overall the side effects were considered manageable.
Kar zadeva celokupno varnost, so se neželeni učinki šteli za obvladljive.
In those receiving Jardiance, cardiovascular events occurred in 10.5% (490 out of 4,687) of patients compared with 12.1% (282 out of 2,333) of patients receiving placebo.
Pri bolnikih, ki so prejemali zdravilo Jardiance, so se kardiovaskularni dogodki pojavili pri 10,5 % (490 od 4 687) bolnikov v primerjavi z 12,1 % (282 od 2 333) bolnikov, ki so prejemali placebo.
This is a summary of the European public assessment report (EPAR) for Jardiance.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Jardiance.
Other information about Jardiance
Druge informacije o zdravilu Jardiance
The full EPAR and risk management plan summary for Jardiance can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Jardiance sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This leads to high levels of glucose in the blood.
To vodi do visokih ravni glukoze v krvi.
The main measure of effectiveness was the occurrence of one of three major cardiovascular events: stroke, heart attack or death caused by cardiovascular disease.
Glavno merilo učinkovitosti je bil pojav enega od treh glavnih kardiovaskularnih dogodkov: kapi, srčnega napada ali smrti zaradi kardiovaskularne bolezni.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Jardiance's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Jardiance večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
A beneficial effect of Jardiance on blood glucose has been shown in four main studies involving over 2,700 patients.
Koristen učinek zdravila Jardiance na glukozo v krvi so zabeležili v štirih glavnih študijah, v katerih je sodelovalo več kot 2 700 bolnikov.
Some of these were continuations of the main studies, and suggested that the benefits of the medicine continued with longer therapy.
Nekatere od njih so bile nadaljevanje glavnih študij, v njih pa so zabeležili, da so se koristi zdravila ohranile z daljšim zdravljenjem.
It is not intended to provide practical advice on how to use Jardiance.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
When blood sugar levels decrease, HbA1C levels also decrease.
Ko ravni glukoze v krvi padejo, se znižajo tudi ravni HbA1C.
What are the risks associated with Jardiance?
Kakšna tveganja so povezana z zdravilom Jardiance?
It can also be used as an ‘add-on' to other diabetes medicines.
Lahko se uporablja tudi kot dodatek k drugim zdravilom za zdravljenje sladkorne bolezni.
What is Jardiance and what is it used for?
Kaj je zdravilo Jardiance in za kaj se uporablja?
What benefits of Jardiance have been shown in studies?
Kakšne koristi je zdravilo Jardiance izkazalo v študijah?
Why is Jardiance approved?
Zakaj je bilo zdravilo Jardiance odobreno?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jardiance have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Jardiance upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
All the studies showed a modest but clinically meaningful decrease in HbA1c with Jardiance compared with placebo: in the study investigating use of Jardiance without other medicines, the reduction in HbA1c was 0.74% more than placebo with the 10 mg dose and 0.85% more than placebo with the 25 mg dose.
Vse študije so pri uporabi zdravila Jardiance pokazale skromno vendar klinično pomembno znižanje ravni HbA1c v primerjavi s placebom: v študiji, v kateri so proučevali uporabo zdravila Jardiance brez dodajanja drugih zdravil, je bilo znižanje ravni HbA1c za 0,74 % višje kot pri placebu ob uporabi 10-miligramskega odmerka in za 0,85 % višje kot pri placebu ob uporabi 25-miligramskega odmerka.
The study involved patients with type 2 diabetes who already had cardiovascular disease (such as angina, heart attack and stroke).
V tej študiji so sodelovali bolniki s sladkorno boleznijo tipa 2, ki so že imeli kardiovaskularno obolenje (kot je angina pektoris, srčni napad in kap).
Jardiance is available as tablets (10 and 25 mg) and can only be obtained with a prescription.
Zdravilo Jardiance je na voljo v obliki tablet (10 in 25 mg), njegovo predpisovanje in izdaja pa je le na recept.
For more information about treatment with Jardiance, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Jardiance preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
There was also supportive evidence suggesting benefit when the medicine was combined with insulin.
Zbrali so tudi podporne dokaze, ki kažejo na koristi zdravila Jardiance v kombinaciji z insulinom.
Jardiance contains the active substance empagliflozin.
Zdravilo Jardiance vsebuje zdravilno učinkovino empagliflozin.
The main measure of effectiveness was the change in the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, after 24 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba ravni snovi v krvi, ki se imenuje glikozilirani hemoglobin (HbA1c), kar označuje uspešnost uravnavanja glukoze v krvi po 24 tednih zdravljenja.
For the full list of all side effects and restrictions with Jardiance, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Jardiance glejte navodilo za uporabo.
Another main study showed that adding Jardiance to usual treatment reduced adverse cardiovascular (heart and blood vessels) effects.
Druga glavna študija je pokazala, da dodajanje zdravila Jardiance običajnemu zdravljenju znižuje neželene kardiovaskularne učinke (učinke na srce in ožilje).
Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri telo ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali pri kateri ga telo ne more učinkovito izrabiti.
Because Jardiance relies on the working of the kidneys for its effect, treatment with this medicine is not recommended in patients with moderately or severely impaired kidney function.
Ker je učinek zdravila Jardiance odvisen od delovanja ledvic, zdravljenje z njim ni priporočljivo za bolnike z zmerno ali hudo okvaro delovanja ledvic.
Jardiance can be used on its own in patients who cannot take metformin (another diabetes medicine).
Zdravilo Jardiance se lahko uporablja kot samostojno zdravilo pri bolnikih, ki ne morejo jemati metformina (drugega zdravila za zdravljenje sladkorne bolezni).
Modest but clinically meaningful reductions in HbA1c were also seen when Jardiance was added to other medicines.
Skromno vendar klinično pomembno znižanje ravni HbA1c so zabeležili tudi pri uporabi zdravila Jardiance v kombinaciji z drugimi zdravili.
The most common side effect with Jardiance (which may affect more than 1 in 10 people) is hypoglycaemia (low blood sugar) when the medicine is taken with a sulphonylurea or insulin.
Najpogostejši neželeni učinek zdravila Jardiance (ki lahko prizadene več kot 1 osebo od 10) je hipoglikemija (nizka raven sladkorja v krvi), kadar se zdravilo uporablja v kombinaciji s sulfonilsečnino ali insulinom.
Jardiance is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled.
Jardiance je zdravilo za zdravljenje sladkorne bolezni, ki se uporablja skupaj z dieto in telesno vadbo za zdravljenje odraslih, katerih sladkorna bolezen tipa 2 ni zadovoljivo uravnana.
For practical information about using Jardiance, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Jardiance naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
However, the blood glucose lowering effects of the medicine are lower in patients with kidney impairment, and the CHMP recommended that the medicine not be used in some patients, depending on their kidney function.
Vendar je učinek zdravila glede zmanjševanja ravni glukoze v krvi manjši pri bolnikih z okvaro ledvic, zato je CHMP priporočil, da se zdravilo Jardiance pri določenih bolnikih ne uporablja, odvisno od njihovega delovanja ledvic.
In addition, the results indicated that Jardiance treatment was associated with a beneficial fall in body weight and blood pressure.
Poleg tega so rezultati pokazali, da je zdravljenje z zdravilom Jardiance povezano s koristnim zmanjšanjem telesne mase in krvnega tlaka.
Jardiance was also shown to reduce cardiovascular events in patients with type 2 diabetes who already had cardiovascular disease.
Zabeležili so tudi, da je zdravilo Jardiance zmanjšalo pojavnost kardiovaskularnih dogodkov pri bolnikih s sladkorno boleznijo tipa 2, ki so kardiovaskularno obolenje že imeli.
If Jardiance is used in combination with insulin or sulphonylureas (medicines that make the body produce insulin), the doses of these may need to be reduced to decrease the risk of hypoglycaemia (low blood sugar levels).
Če se zdravilo Jardiance uporablja v kombinaciji z insulinom ali sulfonilsečninami (zdravili, ki spodbujajo tvorbo insulina), bo za zmanjšanje tveganja hipoglikemije (nizke ravni sladkorja v krvi) morda treba njihov odmerek zmanjšati.
Jardiance was compared with placebo (a dummy treatment) when used alone or added to treatment with other diabetes medicines (metformin, pioglitazone, or metformin plus either pioglitazone or another type of diabetes medicine called a sulphonylurea).
Zdravilo Jardiance so primerjali s placebom (zdravilom brez zdravilne učinkovine), pri čemer so ju uporabili kot samostojni zdravili ali pa dodajali drugim zdravilom za zdravljenje sladkorne bolezni (metforminu, pioglitazonu ali metforminu v kombinaciji s pioglitazonom ali drugim zdravilom za zdravljenje sladkorne bolezni, tj. sulfonilsečnino).
concluded that Jardiance was shown to be effective in lowering blood glucose levels in patients with type 2 diabetes, when given alone or in combination with other diabetes medicines with different mechanisms of action.
Zaključil je, da je zdravilo Jardiance učinkovito pri zmanjševanju ravni glukoze v krvi pri bolnikih s sladkorno boleznijo tipa 2, kadar se zdravilo uporablja kot samostojno zdravilo ali v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni z drugačnimi mehanizmi delovanja.
How does Jardiance work?
Kako zdravilo Jardiance deluje?
As blood is filtered by the kidneys, SGLT2 stops glucose in the bloodstream from being passed out into the urine.
Ko se kri filtrira skozi ledvice, SGLT2 prepreči, da bi se glukoza v krvnem obtoku izločala v urin.
The active substance in Jardiance, empagliflozin, works by blocking a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
Zdravilna učinkovina v zdravilu Jardiance, empagliflozin, zavira beljakovino v ledvicah, imenovano natrijev-glukozni koprenašalec 2 (SGLT2 - sodium glucose cotransporter 2).
How is Jardiance used?
Kako se zdravilo Jardiance uporablja?
By blocking the action of SGLT2, empagliflozin causes more glucose to be removed via the kidney, through the urine, thereby reducing the levels of glucose in the blood.
Empagliflozin z zaviranjem delovanja prenašalca SGLT2 povzroči povečano izločanje glukoze prek ledvic z urinom, kar zniža ravni glukoze v krvi.
In addition, beneficial reductions in weight and blood pressure were seen in patients treated with Jardiance.
Poleg tega so pri bolnikih, zdravljenih z zdravilom Jardiance, zabeležili koristno zmanjšanje telesne mase in znižanje krvnega tlaka.
Animal studies are insufficient.
Študije na živalih niso zadostne.
In some cases you may have to stop using one of the medicines.
V nekaterih primerih boste morda morali nehati jemati eno od teh zdravil.
Many feel normal.
Veliko se jih lahko počuti čisto normalno.
Elderly (age 65 years or over)
Starejši (stari 65 let ali več)
Similar outcomes have been reported with valsartan.
O podobnih izidih so poročali pri valsartanu.
• inability to achieve or maintain erection
• nezmožnost doseganja ali ohranjanja erekcije
In other patients, one or the other effect may be dominant.
Pri drugih bolnikih lahko en od obeh učinkov prevlada.
If you experience this symptom, do not drive or use tools or machines.
Če pride do tega simptoma, ne vozite in ne uporabljajte orodja ali strojev.
* See section 4.4 Photosensitivity
* glejte poglavje 4.4 Fotosenzitivnost
This is especially important if you are using any of the medicines listed below:
To je še posebej pomembno, če jemljete katero od naslednjih zdravil:
Your doctor may need to change the dose or take other precautions.
Zdravnik vam bo morda moral spremeniti odmerek ali upoštevati druge previdnostne ukrepe.
The half-life of valsartan is 6 hours.
Razpolovni čas valsartana je približno 6 ur.
* Based on patient weight of 50 kg
*temelječ na bolnikovi telesni masi 50 kg
Swallow the tablet whole with a glass of water.
Tablete pogoltnite cele, zaužijte jih s kozarcem vode.
Do not take a double dose (two tablets at once) to make up for a forgotten tablet.
Ne vzemite dvojnega odmerka (dveh tablet naenkrat), če ste pozabili vzeti prejšnjo tableto.
If it is almost time for your next dose you should simply take the next tablet at the usual time.
Če je že skoraj čas za naslednji odmerek, enostavno vzemite naslednjo tableto ob običajnem času.
Always take this medicine, even if you are feeling well People who have high blood pressure often do not notice any signs of the problem.
Redno jemljite to zdravilo, tudi če se počutute dobro Ljudje, ki imajo visok krvni tlak, pogosto ne čutijo težav povezanih s tem.
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time.
Če ste pozabili vzeti odmerek tega zdravila, ga vzemite, takoj ko se spomnite in nato vzemite naslednji odmerek ob običajnem času.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.
Vendar tega zmanjšanja AUC ne spremlja klinično pomembno zmanjšanje terapevtskega učinka, zato je valsartan možno dajati bodisi s hrano ali brez nje.
Alcohol, barbiturates or narcotics
alkohol,barbiturati ali narkotiki
Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Uporaba med nosečnostjo je priporočljiva le v primeru, ko ni druge varnejše izbire, in ko bolezen sama predstavlja večje tveganje za mater in plod.
You should see your doctor immediately if you experience any of the following symptoms: Common
Takoj morate k zdravniku, če pride do katerega od naslednjih simptomov: pogosti
• ringing noise in ears
• zvonjenje v ušesih
More than 95% of the absorbed dose is being excreted as unchanged compound in the urine.
Več kot 95 % absorbiranega odmerka se izloči v nespremenjeni obliki z urinom.
Absolute bioavailability has been calculated as between 64% and 80%.
Izračunana absolutna biološka uporabnost je med 64 in 80 %.
When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.
Pri vožnji motornih vozil in uporabi strojev je treba upoštevati, da se občasno lahko pojavi omotica ali utrujenost.
Distribution: Volume of distribution is approximately 21 l/kg.
Porazdelitev: Volumen porazdelitve je približno 21 l/kg.
Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).
Zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), pogostnost neznana (ni mogoče oceniti iz razpoložljivih podatkov).
West Sussex, RH12 5AB United Kingdom
West Sussex, RH12 5AB Velika Britanija
• sudden, temporary loss of consciousness
• nenadna začasna izguba zavesti
D-90429 Nürnberg Germany
D-90429 Nürnberg Nemčija
Distribution: The apparent volume of distribution is 4-8 l/kg.
Porazdelitev: Navidezni volumen porazdelitve je 4-8 l/kg.
One blister contains 7, 10 or 14 film-coated tablets.
En pretisni omot vsebuje 7, 10 ali 14 filmsko obloženih tablet.
All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
Vse naštete spremembe so po 4 tednih okrevanja izzvenele in so bile opredeljene kot pretirani farmakološki učinki.
Do not stop taking your medecine unless your doctor tells you to.
Ne prenehajte jemati zdravila, razen če vam je tako naročil zdravnik.
The combination of these substances has an additive antihypertensive effect.
Kombinacija teh učinkovin ima aditiven antihipertenziven učinek.
• sad mood (depression)
• žalostno razpoloženje (depresija)
• lack of energy
• pomanjkanje energije
Keep your appointments with the doctor even if you are feeling well.
Redno obiskujte zdravnika, tudi če se počutite dobro.
The antihypertensive effect persists over 24 hours after administration.
Antihipertenzivni učinek traja več kot 24 ur po uporabi.
The clinical significance of this effect is uncertain and not sufficient to preclude their use.
Klinični pomen tega učinka ni jasen in ne zadošča za odsvetovanje uporabe teh zdravil.
• increased sensitivity of skin to sun
• povečana občutljivost kože na sončno svetlobo
Using other medicines
Uporaba drugih zdravil
Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.
Glede na vaš odziv na zdravilo vam bo zdravnik nato morda svetoval višji ali nižji odmerek.
Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT.
Zdravnik vam bo praviloma svetoval, da prenehate z jemanjem zdravila Imprida HCT še preden zanosite oziroma takoj, ko ugotovite, da ste noseči in vam bo svetoval jemanje drugega zdravila namesto zdravila Imprida HCT.
It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects.
Zelo pomembno je, da jemljete to zdravilo natančno tako, kot vam naroči zdravnik, da bodo rezultati zdravljenja kar najboljši, možnost neželenih učinkov pa čim manjša.
The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly.
Klinične posledice teh farmakokinetičnih sprememb so lahko izrazitejše pri starejših.